

Bruno Buecher

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7517784/publications.pdf>

Version: 2024-02-01

34
papers

2,212
citations

516710

16
h-index

361022

35
g-index

36
all docs

36
docs citations

36
times ranked

5357
citing authors

#	ARTICLE	IF	CITATIONS
1	Cancer Risks Associated With Germline Mutations in <i>MLH1</i> , <i>MSH2</i> , and <i>MSH6</i> Genes in Lynch Syndrome. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 2304.	7.4	878
2	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. <i>Nature Genetics</i> , 2013, 45, 371-384.	21.4	493
3	Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study. <i>Lancet Oncology</i> , 2018, 19, 1094-1106.	10.7	108
4	Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. <i>Breast Cancer Research</i> , 2012, 14, R33.	5.0	78
5	Prognostic Impact of Residual HPV ctDNA Detection after Chemoradiotherapy for Anal Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 5767-5771.	7.0	68
6	Clinical Validity of HPV Circulating Tumor DNA in Advanced Anal Carcinoma: An Ancillary Study to the Epitopes-HPV02 Trial. <i>Clinical Cancer Research</i> , 2019, 25, 2109-2115.	7.0	65
7	Role of microsatellite instability in the management of colorectal cancers. <i>Digestive and Liver Disease</i> , 2013, 45, 441-449.	0.9	63
8	Familial breast cancer and DNA repair genes: Insights into known and novel susceptibility genes from the GENESIS study, and implications for multigene panel testing. <i>International Journal of Cancer</i> , 2019, 144, 1962-1974.	5.1	50
9	Mutational analysis of anal cancers demonstrates frequent PIK3CA mutations associated with poor outcome after salvage abdominoperineal resection. <i>British Journal of Cancer</i> , 2016, 114, 1387-1394.	6.4	43
10	High-Accuracy Determination of Microsatellite Instability Compatible with Liquid Biopsies. <i>Clinical Chemistry</i> , 2020, 66, 606-613.	3.2	42
11	Contribution of germline deleterious variants in the RAD51 paralogs to breast and ovarian cancers. <i>European Journal of Human Genetics</i> , 2017, 25, 1345-1353.	2.8	39
12	Morphology and genomic hallmarks of breast tumours developed by ATM deleterious variant carriers. <i>Breast Cancer Research</i> , 2018, 20, 28.	5.0	35
13	HPV circulating tumor DNA to monitor the efficacy of anti-PD-1 therapy in metastatic squamous cell carcinoma of the anal canal: A case report. <i>International Journal of Cancer</i> , 2017, 141, 1667-1670.	5.1	29
14	French experts report on MUTYH-associated polyposis (MAP). <i>Familial Cancer</i> , 2012, 11, 321-328.	1.9	23
15	Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 308-316.	2.5	22
16	Clinical relevance of 8q23, 15q13 and 18q21 SNP genotyping to evaluate colorectal cancer risk. <i>European Journal of Human Genetics</i> , 2016, 24, 99-105.	2.8	17
17	Genetic, structural, and functional characterization of POLE polymerase proofreading variants allows cancer risk prediction. <i>Genetics in Medicine</i> , 2020, 22, 1533-1541.	2.4	17
18	Classification of 101 BRCA1 and BRCA2 variants of uncertain significance by cosegregation study: A powerful approach. <i>American Journal of Human Genetics</i> , 2021, 108, 1907-1923.	6.2	14

#	ARTICLE	IF	CITATIONS
19	GENESIS: a French national resource to study the missing heritability of breast cancer. BMC Cancer, 2016, 16, 13.	2.6	13
20	Interaction between IGF2â€³PI3K axis and cancerâ€³associatedâ€³fibroblasts promotes anal squamous carcinogenesis. International Journal of Cancer, 2019, 145, 1852-1859.	5.1	13
21	MUTYH-associated polyposis: Review and update of the French recommendations established in 2012 under the auspices of the National Cancer institute (INCa). European Journal of Medical Genetics, 2020, 63, 104078.	1.3	13
22	Targeted Sequencing of the Mitochondrial Genome of Women at High Risk of Breast Cancer without Detectable Mutations in BRCA1/2. PLoS ONE, 2015, 10, e0136192.	2.5	11
23	National recommendations of the French Genetics and Cancer Group - Unicancer on the modalities of multi-genes panel analyses in hereditary predispositions to tumors of the digestive tract. European Journal of Medical Genetics, 2020, 63, 104080.	1.3	11
24	Mutation screening of MIR146A/B and BRCA1/2 3â€³-UTRs in the GENESIS study. European Journal of Human Genetics, 2016, 24, 1324-1329.	2.8	8
25	Colorectal adenomatous polyposis syndromes: Genetic determinism, clinical presentation and recommendations for care. Bulletin Du Cancer, 2016, 103, 199-209.	1.6	8
26	Prevalence of Pathogenic Variants of FAN1 in More Than 5000 Patients Assessed for Genetic Predisposition to Colorectal, Breast, Ovarian, or Other Cancers. Gastroenterology, 2019, 156, 1919-1920.	1.3	7
27	Bayesian predictive model to assess BRCA2 mutational status according to clinical history: Early onset, metastatic phenotype or family history of breast/ovary cancer. Prostate, 2021, 81, 318-325.	2.3	7
28	Endometrial cancer may be part of the MUTYH-associated polyposis cancer spectrum. European Journal of Medical Genetics, 2022, 65, 104385.	1.3	6
29	Sporadic endometrial adenocarcinoma with MMR deficiency due to biallelic MSH2 somatic mutations. Familial Cancer, 2018, 17, 281-285.	1.9	5
30	Geneâ€³and pathwayâ€³level analyses of iCOGS variants highlight novel signaling pathways underlying familial breast cancer susceptibility. International Journal of Cancer, 2021, 148, 1895-1909.	5.1	5
31	Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective Epitopes-HPV01 and Epitopes-HPV02 studies. European Journal of Cancer, 2022, 162, 138-147.	2.8	4
32	Withholding the Introduction of Antiâ€³Epidermal Growth Factor Receptor: Impact on Outcomes in RAS Wildâ€³type Metastatic Colorectal Tumors: A Multicenter AGEO Study (the WAIT or ACT Study). Oncologist, 2020, 25, e266-e275.	3.7	3
33	Diagnostic chest X-rays and breast cancer risk among women with a hereditary predisposition to breast cancer unexplained by a BRCA1 or BRCA2 mutation. Breast Cancer Research, 2021, 23, 79.	5.0	3
34	MUTYH Status and Colorectal Cancer Risk: Implication for Surveillance. Current Colorectal Cancer Reports, 2015, 11, 10-16.	0.5	0